Live
- Bihar: Inquiry initiated against principal who went to buy veggies during school hours
- TN: DMK postpones executive meet due to heavy rains & Parliament session
- Porous silicon oxide electrodes can fix durability issues in batteries: Researchers
- Jalandhar civic polls: AAP promises launch of 100 e-buses, round the clock water supply
- Economic upliftment of rural women is priority of Tripura govt: CM Saha
- Rajmata Jijabai Trophy: Manipur move to top of the table, T.N register first win
- Italian envoy Baroli hoping to strengthen ties with India through football
- CPI-M revokes suspension of Bengal party leader accused of sexual harassment
- Rachakonda Commissioner Emphasizes Health and Education at Uniform Diet Launch
- BJP leader visits late ASI Surendra Singh in Rajasthan, assures full govt support
Serum Institute of India to manufacture 200 mn doses of Covid-19 vaccine
Serum Institute of India to manufacture 200 mn doses of Covid-19 vaccine
A further collaboration among the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective Covid-19 vaccines for India and low-and middle income countries
New Delhi: A further collaboration among the Serum Institute of India (SII), the world's largest vaccine manufacturer by volume, Gavi and the Bill and Melinda Gates Foundation will accelerate the manufacture and delivery of up to 100 million doses of safe and effective Covid-19 vaccines for India and low-and middle income countries.
This brings the total number of vaccine doses to be covered by the partnership between SII, Gavi, and the Gates Foundation to an aggregate of up to 200 million doses, following the initial agreement for up to 100 million doses announced in August. The arrangement again provides an option to secure additional doses if the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator sees a need for it. The collaboration will provide upfront capital to SII to help it increase manufacturing capacity now so that, once a vaccine, or vaccines, gains regulatory approval and WHO Prequalification, doses can be distributed at scale to LMICs as part of the Gavi COVAX AMC mechanism as early as the first half of 2021.
"The collaboration further bolsters our fight against Covid-19. Through the avid support of Gavi and the Bill & Melinda Gates Foundation, we will now manufacture and deliver up to an additional 100 million doses of immunogenic and safe-proven future Covid-19 vaccines to India and low- and middle-income countries in 2021," said Adar Poonawalla, CEO of Serum Institute of India. He added, "At this stage, it is important for governments, global health and financial institutions in the public and private sector to come together in ensuring that no one is left behind in the road to recovery. This association is in line with our efforts to see that the future vaccines reach the remotest part of the world providing full immunization coverage in a bid to contain the spread of the pandemic."
